Chief Lawyer Xu Xinming

+86-13910160652 ciplawyers@163.com

About Us Consultation

Working Progress

more >

Xu Xinming: Can the Trademark Right of Zhengongfu Beat Bruce Lee’s Portrait Right?
Lasted for Eight Years: Won the Case Concerning the Administrative Dispute over Invalidation of the Invention Patent of Elecon Handled by Lawyer Xu Xinming
IMECAS v. Intel Series Cases of Patent Infringement Disputes
Winning the Case Concerning Dispute over Copyright Transfer Contract of the Musical “Race for Love” Represented by Lawyer Xu Xinming
The Wall Street Journal-Interview-Chief Lawyer Xu Xinming: Delivery Giant Meituan Fined in Beijing’s Tech Crackdown

IP Express

more >

Judicial Development

more >

CASE

more >

IP Theory

more >

IP Practice&View

more >

Determination of "Malice" in Malicious Patent Litigation

07-22 2024

legal System

more >

Chinese Law Library

International Law Library

Return to List

Home > Judicial Development > US&UK > Patent

Insulet wins $452 mln US verdict against EOFlow in insulin pump secrets case

Post time：12-06 2024 Source：Reuters Author：Blake Brittain

tags： Insulet EOFlow trade secret

font-size: +-

563

Dec 5 (Reuters) - Medical device maker Insulet (PODD.O) convinced a jury that Korean rival EOFlow (294090.KQ) owes it $452 million in damages for stealing trade secrets related to insulin pumps, according to a verdict made public in Massachusetts federal court on Thursday.

The jury in its verdict on Tuesday agreed with Insulet that EOFlow stole the Acton, Massachusetts-based company's secrets in order to create a competitor to Insulet's Omnipod, a wearable insulin pump for diabetes patients.

Spokespeople for EOFlow did not immediately respond to a request for comment on the verdict. Insulet president Jim Hollingshead said the company was "extremely pleased" with the verdict.

EOFlow stock was down nearly 30% at the close of Thursday trading on Korea's stock market.

Insulet sued EOFlow last year. Its lawsuit said EOFlow hired away former Insulet employees to develop its EOPatch, an insulin device similar to Insulet's Omnipod.

After failing for six years to design its own patch pump, the lawsuit said EOFlow began selling a "completely redesigned" EOPatch that was "strikingly similar" to the Omnipod less than two years after taking advantage of the former Insulet employees' confidential knowledge.

EOFlow denied the allegations.

Medtronic (MDT.N), opens new tab announced last May that it would acquire EOFlow but canceled the deal last December, citing "multiple breaches" of their agreements.

Previous Next Next

Chief Lawyer Xu Xinming

Working Progress

IP Express

Judicial Development

CASE

The Administrative Dispute over Invalidation of the Invention Patent of Elecon

Rolex trademark infringement case in Kazakhstan: Court should have considered consumer perception

Dispute over Misappropriation of Technical Secrets for Lentinan

IP Theory

IP Practice&View

Determination of "Malice" in Malicious Patent Litigation

legal System

Chinese Law Library

International Law Library

Insulet wins $452 mln US verdict against EOFlow in insulin pump secrets case

Relate Articles

EOFlow Faces Setback in US Entry Due to Patent Dispute with Insulet

Natera Wins $19 Mln US Verdict from ArcherDX in Cancer-Detection Patent Case

Boeing hit with $72 mln verdict in EV aircraft trade secrets case

Insulet secure PI against Medtrum in Paris

IBM wins $45 mln verdict against Zynga in internet tech patent trial

Comment